Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in Alcohol Use Disorder
NCT03252756Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Sep 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing Placebo with Cannabidiol (CBD) (2 arms). Primary endpoints: Trough CBD Plasma Levels at Week 9 and Peak CBD Plasma Levels at Week 8. Started Sep 2019; status: completed.
02
Drugs
cannabidiol
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03252756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252756.